STOCK TITAN

CEL-SCI’s Multikine qualifies for Saudi priority review

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

CEL-SCI Corporation (CVM) announced that its investigational cancer immunotherapy Multikine received official designation under Saudi Arabia’s NADR program, following an application by Amarox, its in-country regulatory and commercialization partner. CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application within the next 2–3 months. NADR-designated products qualify for priority review with a 160-working-day target assessment under guidance effective January 1, 2027; a potential launch in 2027 or early 2028 remains subject to SFDA review and approval.

The FDA full clinical hold remains in place on Multikine’s IND; CEL-SCI must submit requested information and receive FDA notification before starting or resuming studies. FDA cited inadequate safety justification for CEL-SCI’s proposed residual host-cell DNA specification change and inadequate product-quality and comparability information after facility renovations. CEL-SCI says the final product meets FDA-requested specifications and believes it is comparable to product prepared before renovations. It expects to submit requested chemistry, manufacturing and controls information no later than December 10, 2026, and believes the hold should not delay enrollment expected sometime in 2027.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointThe FDA’s October 5, 2026 letter placed a full clinical hold on Multikine’s IND; CEL-SCI must submit requested information and receive FDA notification before initiating or resuming clinical studies.

Filing Explained

The Saudi model assigns CEL-SCI half of net revenue under the partnership’s commercialization arrangement.

Under the existing Saudi partnership, Amarox is CEL-SCI’s exclusive local regulatory representative and commercial distributor. The agreement uses fully funded Saudi marketing, logistics and sales infrastructure; extending it to other Gulf Cooperation Council states is an option, not a completed expansion.

CEL-SCI expects the FDA to find its response acceptable within 30 days, but the FDA’s decision period starts only after receipt of a complete response and does not assure a favorable decision.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Priority assessment target 160 working days NADR pathway guidance effective January 1, 2027.
Planned MAA submission timing Within the next 2–3 months CEL-SCI and Amarox are preparing a Saudi Marketing Authorization Application.
Net revenue-sharing model 50% / 50% CEL-SCI and Amarox’s Saudi Arabia partnership.
Five-year overall survival 73% vs. 45% Multikine versus standard of care alone in the Phase 3 target population (p = 0.0015).
Expected CMC information submission No later than December 10, 2026 CEL-SCI expects to submit requested information to the FDA.
FDA decision period 30 calendar days The stated period begins upon receipt of a complete response and does not assure a favorable decision.
New Accelerator Program for Drugs in Rare Diseases (NADR) regulatory
"New Accelerator Program for Drugs in Rare Diseases (NADR)"
Marketing Authorization Application (MAA) regulatory
"submit a Marketing Authorization Application (MAA) to the SFDA"
A marketing authorization application (MAA) is a formal request submitted to a health regulator asking permission to sell a medicine or medical product in a market. Think of it like applying for a driver's license for a new drug: the regulator checks safety, quality and effectiveness before granting permission. For investors, the MAA stage matters because approval typically unlocks commercial sales and revenue, while rejection or delay creates major value and timing risk.
full clinical hold regulatory
"placed a full clinical hold"
residual host-cell DNA specification technical
"change the residual host-cell DNA specification"
chemistry manufacturing and controls technical
"requested chemistry manufacturing and controls information"
neoadjuvant treatment medical
"neoadjuvant treatment with Multikine before standard of care"
Neoadjuvant treatment is medicine given before the main therapy—usually surgery—to shrink a tumor or slow disease so the primary treatment has a better chance of working. Think of it as trimming branches before cutting down a tree: it can make the main procedure easier, less risky, or more successful. For investors, neoadjuvant success can speed regulatory approval, expand a drug’s market by showing clear clinical benefit earlier, and boost commercial prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the expected Saudi review timeline for Multikine (CVM)?

NADR-designated products have a 160-working-day target assessment under SFDA guidance effective January 1, 2027. CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application within the next 2–3 months; any commercial launch remains subject to SFDA review and approval.

What must CEL-SCI do to address the FDA hold on Multikine?

CEL-SCI must submit a complete response and receive FDA notification before initiating or resuming clinical studies. The FDA’s stated 30-calendar-day decision period begins only after receipt of a complete response and does not assure a favorable decision.

What are CEL-SCI’s commercial terms with Amarox in Saudi Arabia?

Amarox is CEL-SCI’s local regulatory representative and exclusive commercial distributor for Multikine in Saudi Arabia. The partnership provides for a 50% / 50% net revenue-sharing model and includes an option to expand the commercial framework into other Gulf Cooperation Council member states.

What five-year survival result did Multikine report in its Phase 3 target population?

The cited study reported 73% five-year overall survival with Multikine versus 45% with standard care alone (p = 0.0015) in the target population.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) November 20, 2026

 

CEL-SCI CORPORATION

(Exact name of registrant as specified in its charter)

 

Colorado

 

001-11889

 

84-0916344

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

8229 Boone Blvd. #802

Vienna, VA22182

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code (703) 506-9460

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

CVM

 

NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§203.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§204.12b-2 of this chapter.

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

 

 

 

 

Item 8.01Other Events.

 

(a) On November 20, 2026, CEL-SCI Corporation, a Colorado corporation (the “Company”) issues a press release announcing that its investigational cancer immunotherapy Multikine® has been granted official designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). The designation application was successfully submitted by Amarox, CEL-SCI’s in-country regulatory and commercialization partner in Saudi Arabia. This is the release:

 

On November 20, 2026, CEL-SCI Corporation, a Colorado corporation (the “Company”) announced that its investigational cancer immunotherapy Multikine® (Leukocyte Interleukin, Injection) has been granted official designation under the Saudi Food and Drug Authority’s (SFDA) New Accelerator Program for Drugs in Rare Diseases (NADR). The designation application was successfully submitted by Amarox, CEL-SCI’s in-country regulatory and commercialization partner in Saudi Arabia.

 

The NADR designation positions Saudi Arabia to potentially become the first commercial market globally for Multikine®. With NADR status secured, CEL-SCI and Amarox are preparing to submit a Marketing Authorization Application (MAA) to the SFDA within the next 2-3 months. Under recently enacted SFDA guidance, products designated under the NADR pathway qualify for priority review with a target assessment timeframe of 160 working days, supporting a potential commercial launch and initial commercial sales of Multikine in 2027 or early 2028, pending SFDA approval and review of the MAA.

 

“The Saudi FDA has demonstrated extraordinary global regulatory leadership by establishing the NADR program,” stated Geert Kersten, Chief Executive Officer of CEL-SCI. “Their forward-looking framework perfectly aligns with Saudi Vision 2030’s mandate to bring cutting-edge healthcare innovations to the Kingdom rapidly. Because of the SFDA's proactive approach, we are prioritizing Saudi Arabia as the potential first global commercial market for Multikine. Supported by Amarox’s deep in-country capabilities, we are not only advancing our commercialization strategy but also supporting the Kingdom’s goal of building robust, localized biopharmaceutical infrastructure. This partnership de-risks our commercial transition while delivering on our shared commitment to urgently bring life-extending therapies to head and neck cancer patients. Multikine® will initially be supplied from CEL-SCI’s US based manufacturing facility.”

 

“Our partnership with CEL-SCI represents an important step in Saudi Amarox’s strategy to expand into innovative medicines, advanced therapies, and biotechnology,” said Dr. Abdullah Alzomaie, Founder and Chief Executive Officer of Saudi Amarox. “We are proud of CEL-SCI’s confidence in Amarox as its regional partner, and we are pleased to see our collaboration achieve an important early milestone through the SFDA’s NADR designation for Multikine. This progress reflects the encouraging environment Saudi Arabia is creating under Vision 2030 to support medical innovation, scientific research, and the introduction of advanced therapies. We see this as the beginning of a promising and long-term partnership.”

 

 

2

 

 

 

Accelerated Regulatory Pathway Aligned with Saudi Vision 2030

 

Launched by the SFDA in August 2026, the NADR program is a cornerstone initiative supporting the healthcare transformation goals of Saudi Vision 2030 and the Kingdom's National Biotechnology Strategy. NADR is designed to expedite the evaluation of breakthrough therapies that address serious diseases with high unmet medical needs, ensuring Saudi citizens have first-in-class access to advanced medicines. Key benefits of the designation include:

 

 

•

Priority 160-Working-Day Assessment: Eligibility for accelerated review under SFDA submission guidance effective January 1, 2027, establishing a clear pathway for a potential 2027 or early 2028 Multikine launch.

 

•

Collaborative Regulatory Framework: Dedicated access to scientific advice and tailored evaluation frameworks, reflecting the SFDA's commitment to agile, science-based regulation.

 

•

Streamlined Access Pathways: Accelerated frameworks designed to bring high-impact immunotherapies to patients rapidly.

 

Capital-Efficient Commercialization & Local Capability Building

 

Under the terms of the strategic partnership announced in May 2026, Amarox is CEL-SCI’s local regulatory representative and exclusive commercial distributor for Multikine in Saudi Arabia. Beyond establishing a capital-efficient, 50% / 50% net revenue-sharing model for CEL-SCI, the partnership directly supports Saudi Arabia's localization goals by utilizing fully funded, in-country marketing, logistics, and sales infrastructure. The agreement also includes an option to expand this localized commercial framework into the broader Gulf Cooperation Council (GCC) member states—including the United Arab Emirates, Kuwait, Qatar, Bahrain, and Oman.

 

Compelling Phase 3 Clinical Foundation

 

CEL-SCI intends to seek marketing authorization in Saudi Arabia for the exact target population defined in its planned U.S. registration study: newly diagnosed, previously untreated adult patients with locally advanced, resectable oral cavity squamous cell carcinoma with no lymph node involvement and low/zero tumor PD-L1 expression.

 

In the world’s largest Phase 3 study for locally advanced head and neck cancer, neoadjuvant treatment with Multikine® before standard of care (SOC) delivered dramatic survival benefits in this target population:

 

 

•

73% 5-Year Overall Survival vs. 45% for SOC alone (p = 0.0015).

 

•

66% Relative Reduction in Risk of Death compared to SOC alone (Hazard Ratio = 0.34).

 

•

Strong Neoadjuvant Mechanism: Administered locally over three weeks immediately following diagnosis, activating an intact immune system prior to surgery, radiation, and chemotherapy.

 

First Berlin, based in Berlin, Germany, which facilitated the partnership, continues to support CEL-SCI and Amarox as the program moves towards submission and launch in the Kingdom.

 

 

3

 

 

 

About Multikine

 

Multikine is a novel cancer immunotherapy administered before surgery as a treatment for newly diagnosed previously untreated locally advanced head and neck cancer. It is manufactured at scale, stored in a vial, and injected directly around the tumor. Its goal is to activate a person’s immune system to fight cancer before the ravages of surgery, radiation and chemotherapy have weakened the immune system. In the world’s largest locally advanced head and neck cancer Phase 3 study, Multikine increased the 5-year survival rate of the target patient population to 73% vs 45% in patients treated with standard of care alone and halved the risk of death from 55% to 27%.

 

About CEL-SCI Corporation

 

CEL-SCI believes that boosting a patient’s immune system before surgery, radiotherapy and chemotherapy have damaged it, should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor.

 

Multikine (Leukocyte Interleukin, Injection), given right after diagnosis and before surgery, has been administered to over 740 patients and has an excellent safety profile compared to other cancer drugs. It has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.

 

The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

 

(b) The FDA’s October 5, 2026 letter placed a full clinical hold communicated on September 17, 2026. The FDA identified insufficient information to assess risks to human subjects, including: (a) inadequate safety justification for the request to change the residual host-cell DNA specification of the Multikine final product. It is of note that the Multikine final product currently meets the specifications that FDA has requested. This issue was raised because CEL-SCI requested a higher level than the existing specification. CEL-SCI does not believe that this represents a safety risk to patients because Multikine is made from cells in short term culture and the regulation that FDA is applying is for cells made in continuous cell lines. (b) inadequate information relating to product quality and comparability following manufacturing-facility renovations. CEL-SCI believes that the product is comparable to Multikine prepared prior to the renovations. We must submit the requested information and receive FDA notification before we can initiate or resume clinical studies under the Multikine IND. Historical clinical safety observations, institutional review board approval and submission of a response do not automatically lift the hold. The FDA may find our response incomplete or inadequate or require additional information or work. Its stated 30-day decision period begins only upon receipt of a complete response and does not assure a favorable decision.

 

The Company has hired Ergomed, the same company that ran its previous head and neck cancer Phase 3 study, to commence the follow-up Phase 3 study required by FDA prior to registration. Renovation updates, commissioning of the manufacturing facility in which Multikine is produced have occurred since completion of the previously completed Phase 3 study with Multikine.

 

 

4

 

 

 

The investigational new drug (IND) regulations (21CFR 312.40) allow a clinical trial of an investigational new drug to begin within 30 days of a sponsor’s filing an IND with the FDA for review. However, the regulations also provide that the FDA may place a Clinical Hold on the study if within the 30-day review period they find the information provided in the IND is insufficient to resolve safety or technical questions they may have.

 

A Clinical hold may be placed by the FDA before a new study is initiated or when a study underway. More commonly and as is the case for CEL-SCI, clinical holds are placed before studies are initiated in order to resolve technical or safety issues. Clinical holds are generally placed before studies for insufficient information regarding chemistry manufacturing and controls (CMC), preclinical toxicology reports, or insufficient justification for the starting dose or protocol design deficiencies. Once CEL-SCI submits a “Complete Response” addressing the FDA’s questions, the agency is legally required to review it and decide whether or not to lift the hold within 30 calendar days. A pre-study clinical hold, as the one for CEL-SCI, extends the regulatory review period, but may be resolved in a reasonable period of time. The chemistry manufacturing and controls information the FDA has requested of the Company is being compiled and is expected to be submitted to the FDA no later than December 10, 2026. The company is of the belief that the information will be found acceptable to the FDA within the 30-day review period and, if the FDA makes such determination, the clinical hold therefore would be lifted. As the clinical trial was not expected to begin enrollment until sometime in 2027, CEL-SCI believes the placement of the clinical hold now should not delay enrollment.

 

Forward-Looking Statements

 

Certain of the statements made in this Current Report on Form 8-K are forward looking, including, without limitation, statements regarding the Company’s plans to compile and submit the chemistry, manufacturing and controls information requested by the FDA and the timing of such submission; the Company’s belief that such information will be found acceptable to the FDA within the 30-day review period; the expected lifting of the full clinical hold; the anticipated timing of the commencement of patient enrollment in the follow-up Phase 3 study, including the expectation that enrollment will begin sometime in 2027 and that the clinical hold should not delay enrollment; and the potential benefits of the designation of Multikine under the SFDA’s New Accelerator Program for Drugs in Rare Diseases. Actual results or developments may differ materially from those projected or implied in these forward-looking statements, including as a result of the FDA determining that the information submitted by the Company is insufficient, requesting additional information, or otherwise declining to lift the full clinical hold, or delays in finalizing contracts with clinical study sites and investigators or obtaining institutional review approval. More information about the risks and uncertainties faced by the Company is contained under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 filed with the SEC on December 29, 2025, and other filings made by the Company with the SEC, all of which can be obtained on the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 

 

5

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 20, 2026

 

 

CEL-SCI CORPORATION

 

 

 

 

 

 

By:

/s/ Geert Kersten

 

 

 

Geert Kersten

 

 

 

Chief Executive Officer

 

 

 

6

 

Filing Exhibits & Attachments

5 documents

Keep reading